Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share

Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results

August 31, 2017 4:01 PM EDT

ATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ: AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017.

We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives, commented Joseph M. Patti, PhD, President and Chief Executive Officer of Aviragen Therapeutics. Importantly, we have also taken actions to minimize cash spending in order to maintain the Companys solid financial position as evidenced by our reported cash position of $38.6 million.

... More